|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: UBAP2 |
Gene summary for UBAP2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | UBAP2 | Gene ID | 55833 |
| Gene name | ubiquitin associated protein 2 | |
| Gene Alias | UBAP-2 | |
| Cytomap | 9p13.3 | |
| Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | Q5T6F2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55833 | UBAP2 | CCI_1 | Human | Cervix | CC | 1.39e-12 | 1.11e+00 | 0.528 |
| 55833 | UBAP2 | CCI_2 | Human | Cervix | CC | 3.31e-11 | 1.28e+00 | 0.5249 |
| 55833 | UBAP2 | CCI_3 | Human | Cervix | CC | 6.40e-08 | 8.51e-01 | 0.516 |
| 55833 | UBAP2 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.96e-19 | -4.58e-01 | 0.0155 |
| 55833 | UBAP2 | HTA11_2487_2000001011 | Human | Colorectum | SER | 2.09e-03 | -3.70e-01 | -0.1808 |
| 55833 | UBAP2 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 9.24e-14 | -3.04e-01 | 0.294 |
| 55833 | UBAP2 | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 1.42e-03 | 8.32e-01 | 0.3487 |
| 55833 | UBAP2 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 1.11e-02 | 5.04e-01 | 0.281 |
| 55833 | UBAP2 | F007 | Human | Colorectum | FAP | 2.05e-02 | -2.96e-01 | 0.1176 |
| 55833 | UBAP2 | A001-C-207 | Human | Colorectum | FAP | 4.89e-03 | -2.68e-01 | 0.1278 |
| 55833 | UBAP2 | A015-C-203 | Human | Colorectum | FAP | 7.15e-28 | -4.02e-01 | -0.1294 |
| 55833 | UBAP2 | A015-C-204 | Human | Colorectum | FAP | 7.96e-05 | -3.01e-01 | -0.0228 |
| 55833 | UBAP2 | A014-C-040 | Human | Colorectum | FAP | 1.24e-05 | -4.77e-01 | -0.1184 |
| 55833 | UBAP2 | A002-C-201 | Human | Colorectum | FAP | 1.94e-09 | -2.30e-01 | 0.0324 |
| 55833 | UBAP2 | A002-C-203 | Human | Colorectum | FAP | 2.29e-04 | -9.91e-02 | 0.2786 |
| 55833 | UBAP2 | A001-C-119 | Human | Colorectum | FAP | 1.61e-04 | -1.27e-01 | -0.1557 |
| 55833 | UBAP2 | A001-C-108 | Human | Colorectum | FAP | 2.67e-15 | -1.86e-01 | -0.0272 |
| 55833 | UBAP2 | A002-C-205 | Human | Colorectum | FAP | 1.29e-19 | -3.16e-01 | -0.1236 |
| 55833 | UBAP2 | A015-C-006 | Human | Colorectum | FAP | 1.31e-13 | -2.81e-01 | -0.0994 |
| 55833 | UBAP2 | A015-C-106 | Human | Colorectum | FAP | 9.14e-10 | -1.50e-01 | -0.0511 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0048872111 | Esophagus | ESCC | homeostasis of number of cells | 163/8552 | 272/18723 | 1.40e-06 | 1.69e-05 | 163 |
| GO:003406315 | Esophagus | ESCC | stress granule assembly | 23/8552 | 26/18723 | 6.82e-06 | 6.90e-05 | 23 |
| GO:00340633 | Liver | NAFLD | stress granule assembly | 9/1882 | 26/18723 | 6.56e-04 | 8.50e-03 | 9 |
| GO:00488727 | Liver | NAFLD | homeostasis of number of cells | 43/1882 | 272/18723 | 1.86e-03 | 1.91e-02 | 43 |
| GO:00340632 | Liver | HCC | stress granule assembly | 24/7958 | 26/18723 | 1.35e-07 | 2.57e-06 | 24 |
| GO:004887222 | Liver | HCC | homeostasis of number of cells | 147/7958 | 272/18723 | 7.48e-05 | 6.70e-04 | 147 |
| GO:004887220 | Oral cavity | OSCC | homeostasis of number of cells | 152/7305 | 272/18723 | 1.08e-08 | 2.23e-07 | 152 |
| GO:00340637 | Oral cavity | OSCC | stress granule assembly | 21/7305 | 26/18723 | 1.66e-05 | 1.64e-04 | 21 |
| GO:003406314 | Oral cavity | LP | stress granule assembly | 14/4623 | 26/18723 | 1.33e-03 | 1.07e-02 | 14 |
| GO:0048872110 | Oral cavity | LP | homeostasis of number of cells | 87/4623 | 272/18723 | 3.75e-03 | 2.47e-02 | 87 |
| GO:004887218 | Prostate | BPH | homeostasis of number of cells | 79/3107 | 272/18723 | 1.79e-07 | 3.99e-06 | 79 |
| GO:00340636 | Prostate | BPH | stress granule assembly | 15/3107 | 26/18723 | 2.37e-06 | 3.83e-05 | 15 |
| GO:004887219 | Prostate | Tumor | homeostasis of number of cells | 86/3246 | 272/18723 | 5.29e-09 | 2.11e-07 | 86 |
| GO:003406313 | Prostate | Tumor | stress granule assembly | 15/3246 | 26/18723 | 4.17e-06 | 6.64e-05 | 15 |
| GO:004887229 | Skin | cSCC | homeostasis of number of cells | 104/4864 | 272/18723 | 5.34e-06 | 7.71e-05 | 104 |
| GO:003406316 | Skin | cSCC | stress granule assembly | 17/4864 | 26/18723 | 2.77e-05 | 3.11e-04 | 17 |
| GO:003406317 | Thyroid | PTC | stress granule assembly | 21/5968 | 26/18723 | 3.95e-07 | 6.55e-06 | 21 |
| GO:0048872113 | Thyroid | PTC | homeostasis of number of cells | 125/5968 | 272/18723 | 7.25e-07 | 1.14e-05 | 125 |
| GO:00614841 | Thyroid | PTC | hematopoietic stem cell homeostasis | 11/5968 | 18/18723 | 1.00e-02 | 4.07e-02 | 11 |
| GO:0048872210 | Thyroid | ATC | homeostasis of number of cells | 135/6293 | 272/18723 | 2.92e-08 | 5.50e-07 | 135 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| UBAP2 | SNV | Missense_Mutation | c.560N>T | p.Ser187Leu | p.S187L | Q5T6F2 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| UBAP2 | SNV | Missense_Mutation | c.1852N>C | p.Asp618His | p.D618H | Q5T6F2 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-A7-A13F-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
| UBAP2 | SNV | Missense_Mutation | c.558N>G | p.Phe186Leu | p.F186L | Q5T6F2 | protein_coding | deleterious(0.04) | benign(0.261) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| UBAP2 | insertion | Frame_Shift_Ins | novel | c.2976_2977insTTTTATT | p.Lys993PhefsTer3 | p.K993Ffs*3 | Q5T6F2 | protein_coding | TCGA-A8-A09C-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| UBAP2 | insertion | Nonsense_Mutation | novel | c.2975_2976insAAGGTAAGTGTCTACAGGTAAAATTAGGA | p.Asn992LysfsTer3 | p.N992Kfs*3 | Q5T6F2 | protein_coding | TCGA-A8-A09C-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| UBAP2 | insertion | Nonsense_Mutation | novel | c.578_579insGTGAATAATTG | p.Phe194Ter | p.F194* | Q5T6F2 | protein_coding | TCGA-A8-A09D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR | ||
| UBAP2 | insertion | Frame_Shift_Ins | novel | c.577_578insGATCATCAAGGGAAGGTGAGAA | p.Thr193ArgfsTer10 | p.T193Rfs*10 | Q5T6F2 | protein_coding | TCGA-A8-A09D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR | ||
| UBAP2 | insertion | Nonsense_Mutation | novel | c.2798_2799insGTGAACCTAGGAGGCGGAGCTTGCAGTGAGCCGAGATCTCGCC | p.Pro934Ter | p.P934* | Q5T6F2 | protein_coding | TCGA-AO-A0JF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD | ||
| UBAP2 | deletion | Frame_Shift_Del | novel | c.2287_2299delNNNNNNNNNNNNN | p.Asn763AlafsTer22 | p.N763Afs*22 | Q5T6F2 | protein_coding | TCGA-B6-A3ZX-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD | ||
| UBAP2 | insertion | In_Frame_Ins | novel | c.2748_2749insCCC | p.Pro916dup | p.P916dup | Q5T6F2 | protein_coding | TCGA-D8-A1JF-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |